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Abstract Alternatively spliced exons generally contain weak
splicing sites, and exonic and/or intronic regulatory elements
recognised by trans-acting auxiliary splicing factors. The EDA
exon of the fibronectin gene is a typical example of an exon
bearing a purine-rich exon splicing enhancer (ESE) element
recognised by members of the SR phosphoprotein family. The
regulatory region that governs splicing in the human EDA exon
also contains an exon splicing silencer (ESS) element. We have
cloned the mouse EDA genomic region, and we show that the
ESE and the ESS elements, although they have base differences,
can be replaced by the human elements without significant
change in the exon inclusion/exclusion ratio. This fact suggests a
common splicing regulatory mechanism across species. We
demonstrate in vivo the functional activity of the mouse ESE
element in splicing. We also show that the trans-acting factors
recognising this element cooperate with the 5P splicing site of the
EDA exon to facilitate proper exon recognition. Indeed, a strong
5P splicing site overrides the ESE function in exon recognition.
However, the presence of a strong 3P splicing site is not sufficient
to compensate for the absence of the splicing enhancer. Our data
provide in vivo evidence of the interplay between the exonic
splicing regulatory elements and the splicing sites, leading finally
to subtle regulation of alternative splicing.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Pre-mRNA alternative splicing provides an additional
source of genetic and biochemical £exibility for the cell [1].
The alternative splicing process can be regulated in a tempo-
ral, tissue-speci¢c or developmental manner. The accurate ex-
cision of an exon from the pre-mRNA requires not only base
pairing interactions between the 5P splicing site and the 5P
terminus of U1 snRNA, and between the branch site and
an internal region of U2 snRNA, but also a combination of
trans-acting factors which are essential for the e⁄cacy and
precision of splicing.
Recently it was seen that exon sequences in£uence splicing
site selection. A variety of exon splicing enhancer (ESE) se-
quences, stimulating the removal of introns with weak splicing
signals, have been identi¢ed in constitutive and alternative
splicing processes [2^6]. Many of these sequences contain a
(GAR)n motif were R is a purine [7]. Di¡erent laboratories
have shown that these enhancer elements are able to bind
members of a family of serine/arginine-rich splicing factors
named SR proteins [8^11]. The SR protein:pre-mRNA bind-
ing seems to be a very early step in spliceosome assembly [12].
Recent in vitro studies indicated that SR proteins promote the
¢rst step of spliceosome assembly assisting the association of
the 5P splicing site with the U1 snRNP [10,13,14] and the 3P
splicing site with the U2AF splicing factor [10].
The ¢bronectin (FN) gene represents an excellent system to
study the molecular basis for alternative splicing [15^17]. Al-
ternative RNA processing of human FN pre-mRNA occurs in
three regions of the primary transcript called EDA, EDB and
IIICS. EDA and EDB both encode a type III structural repeat
and exhibit exon skipping while IIICS undergoes a complex
splicing pattern that in humans generates ¢ve variants. As a
consequence there are 20 di¡erent FN messengers, expression
of which is regulated in a tissue-speci¢c and developmental
fashion as well as in response to physiological and patholog-
ical conditions.
EDA alternative splicing can be accurately reproduced in
HeLa cells by transient expression of a three-exon hybrid FN-
K-globin minigene [18]. Using this approach Mardon et al.
[19] obtained the ¢rst evidence of the involvement of exonic
sequences, not related to the splicing sites, in the mechanism
of exon recognition. Deletion or replacement of 81 nucleotides
located internally in the EDA exon abolished alternative splic-
ing and resulted in the omission of the EDA exon from the
mature FN mRNA. Previously, we and others have charac-
terised the exonic sequences involved in the processing of the
human EDA exon [2,8], describing that two distinct elements
regulate the inclusion of the EDA exon with opposite e¡ects.
A short polypurine sequence (GAAGAAGA) acts as a splic-
ing enhancer element (ESE) [2,8], while a downstream se-
quence (CAAGG) negatively a¡ects the inclusion of the
exons, thus acting as an exonic splicing silencer (ESS) [2].
Furthermore, Lavigueur et al. [8] have demonstrated that
members of the SR protein splicing regulatory family interact
with the polypurinic enhancer element of the EDA exon. The
bipartite arrangement of cis-regulatory sequences seems to be
common to other systems as recently established by other
researchers [20^23].
Recently the presence of two additional exonic splicing reg-
ulatory elements in the EDA exon was reported, a silencer
associated with a conserved RNA secondary structure, and
a non-purine-rich splicing enhancer. Both elements are located
in the 5P region of the EDA exon [24].
There is a wealth of information regarding the mechanism
of human ¢bronectin alternative splicing. Nucleotide sequence
comparison with other species suggests a conservation of such
a mechanism, although no study has been carried out up to
date to experimentally con¢rm this assumption. The case of
the mouse FN pre-mRNA processing is particularly interest-
ing because the bene¢ts of studying FN alternative splicing
could be twofold. Firstly it will provide an extended knowl-
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edge of the splicing mechanism and secondly it will make it
possible to carry out very speci¢c germ line manipulations
that may shed light on the biological function of the FN iso-
forms generated by the alternative splicing process.
In the present work we characterise in vivo the purine-rich
exonic enhancer element in the EDA exon of the mouse ¢-
bronectin gene, and extend the study of this system to the
cross-communication that occurs between the ESE, trans-act-
ing factors, and 5P and 3P splicing sites.
2. Materials and methods
2.1. Plasmids construction
A 12 kb FN fragment from a c129 genomic DNA lambda DashII
library (a gift from Glenn Friedrich) was subcloned into pBSKSII and
a 3988 bp KpnI-KpnI fragment subcloned into pBSKSII and com-
pletely sequenced. All DNA manipulations were done as described
[25]. The numbering cited in the text refers to the KpnI-KpnI 3988
bp sequence. GenBank accession number AF095690.
A KpnI site was introduced at position 220 by replacing the 3P end
of the EDA previous exon up to the PstI site (nt 286) with a double
stranded synthetic oligonucleotide. A NotI site was introduced in the
EDA +1 exon at nt 2856 by PCR-directed mutagenesis. The complete
2656 bp genomic region comprising 77, 104, 1035 and 1170 of the
EDA £anking exons and introns respectively, cloned at the KpnI and
NotI sites of the pBSKSII vector, was excised, made blunt and sub-
cloned into the BstEII site of pSVK1 [18]. This clone, containing the
entire genomic region from the EDA 31 exon to the EDA +1 exon
inserted in the third exon of the K-globin gene, was called pFN-
EDAwt.
To produce the pFN-vEDA plasmid, the pFN-EDAwt was cut
with NdeI and re-ligated, resulting in the excision of the 715 bp frag-
ment containing the EDA exon. The NdeI 715 bp fragment was sub-
cloned into the NdeI site of pET16, then XbaI-EcoRI cut and sub-
cloned into pUC19 (clone 29) and PCR-mutagenised to obtain all the
mutants. To obtain the vA mutation (GAAGAC deletion of the ESE,
nt 1487^1492), a synthetic oligonucleotide containing the ESE dele-
tion was introduced at the Bsu36I sites of clone 29. The resulting 709
bp NdeI-NdeI fragment was introduced in the NdeI site of the pFN-
vEDA to generate the pFN-EDA-vA plasmid. The pFN-EDA-v76
and pFN-EDA-v88 deletion constructs were made by cutting clone 29
with Bsu36I, and partially digesting the ends with S1 nuclease, fol-
lowed by ligation with T4DNA ligase. As described before, the NdeI-
NdeI inserts were introduced in the pFN-vEDA plasmid.
The GAAGACGA (Am element) and CAGGG (Bm element) se-
quences of clone 29 were converted to GAAGAAGA (Ah) and
CAAGG (Bh) respectively by PCR-directed mutagenesis. The 715
bp NdeI-NdeI resulting fragments were inserted into the pFN-
vEDA plasmid to generate the pFN-EDA AmBh, pFN-EDA
AhBm and pFN-EDA AhBh plasmids.
The 5P splicing site mutant was created by converting the wild type
CAG:GTATTG sequence to the 5P splicing site consensus sequence
CAG:GTAAGT by PCR-directed mutagenesis. The wild type 3P splic-
ing site of the EDA exon was replaced by the 3P splicing site of the
second exon of the human apolipoprotein (Apo) A1 gene {CCCTCC-
TCCTCCTTCTTCTTCTTCAG:(A/G)}.
For double and triple mutant constructs, XhoI was used to inter-
change the 5P and 3P regions containing single or double mutations.
The double 5P splicing site mutant plus the vA deletion was made by
PCR-directed mutagenesis as described above.
2.2. Cell transfections and RNA analysis
5U105 NIH3T3, Hep3B, HepG2, HeLa, N-Muli mouse liver or
LMM3 mouse mammary [26] cells grown in 6 cm diameter plates
were transfected with 5 Wg of each construct by the calcium phosphate
precipitate method or with lipofectin (Boehringer) as described [2].
The cells were harvested 40 h after the transfection and total RNA
was prepared with RNAzol following the manufacturer’s instructions.
The cDNA was made using MMTV-RT and oligo-dT primer from
1 Wg of total RNA. PCR reactions were done in linear conditions as
previously described [2,27^29]. Brie£y, the primers KG-FN dir (5P-C-
ACTGCCTGCTGGTGACGTAC-3P) and KG-FN rev (5P-TGGGC-
GGCCAGGGTCACGGC-3P) were used for the PCR reactions (60‡C
of annealing for 45 s, 72‡C elongation for 45 s and 92‡C denaturation
for 45 s, for 30 PCR cycles). Both primers are speci¢c for the mRNA
transcribed from the transfected constructs and can discriminate the
mRNA transcribed by host globin and ¢bronectin genes. The last 3P
bases match the residual linker sequences from globin and ¢bronectin
exons. The PCR products were visualised in an ethidium bromide
1.6% agarose gel, photographed and subjected to densitometric anal-
ysis. The cell transfection experiments and RNA analysis were per-
formed several times and representative experiments are shown in the
¢gures.
3. Results
The murine genomic EDA region was cloned from a ge-
nomic c129 DNA library and comparison between the murine
and the human EDA exon showed a perfect matching of the
3P and 5P splicing sites (Fig. 1), and revealed single base di¡er-
ences in each of the previously reported exonic regulators [2].
The polypurine sequence present in humans was interrupted
in the mouse by a pyrimidine and also the putative mouse
silencer splicing element contained one base change when
compared with the human one (Fig. 1).
The splicing enhancer and silencer elements were originally
de¢ned in the human EDA by speci¢c deletions, transient
transfection of an K-globin-FN hybrid minigene and subse-
quent analysis of the transcribed mRNA [2,18,19]. We devised
a similar approach to study the splicing mechanism governing
the mouse EDA exon. The entire murine genomic region was
cloned at the BstEII site of the third exon of the K-globin gene
and the minigene constructs were transiently transfected into
di¡erent cell types (NIH3T3, Hep3B, HepG2, HeLa, N-Muli
mouse liver and LMM3 cells).
Alternative splicing was detected after transient transfection
with the pSVED-mEDA wt construct re£ecting the endoge-
nous alternative splicing pattern characteristic of the di¡erent
cell types, and the splicing products obtained with each con-
struct were similar in the various cell lines. The results ob-
tained with NIH3T3 cells are shown in Fig. 2.
Constitutive exon skipping was observed when a deletion of
the mouse polypurine element was tested, as shown in Fig. 2
(pSVED-mEDA-vA construct, lane 2). This result indicates
that this element strongly stimulates splicing of the EDA
exon. No signi¢cant di¡erences were seen when the mouse
GAAGACGA splicing enhancer sequence (Am) was mutated
to generate the longer GAAGAAGA polypurine element (Ah)
present in the human EDA sequence, as is the case for the
pSVED-mEDA-AhBm construct (Fig. 2, lane 6). This reveals
that the mouse exonic enhancer element stimulates splicing of
the EDA exon in a similar manner as the human counterpart
regardless of its shorter polypurine tract. Moreover, wider
deletions of 76 and 88 bases centred in the A element com-
pletely abolish exon recognition (see Fig. 2, lanes 3 and 4,
pSVED-mEDA-v76 and pSVED-mEDA-v88 constructs),
having the same splicing e⁄ciency as the pSVED-mEDA-
vA construct.
In the pSVED-mEDA AmBh construct the CAGGG se-
quence of the mouse B element (Bm) was mutated to resemble
the human one (Bh, see Fig. 1). Its splicing pattern was iden-
tical to the wt one. A similar result was obtained with the
pSVED-mEDA AhBh construct, in which both A and B ele-
ments sequences were mutated to the human ones (Fig. 2,
lanes 5 and 7). These results indicate that both the human
polypurinic enhancer and the silencer element sequences are
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functional in the mouse context, and may function via anal-
ogous mechanisms.
To understand the mechanism by which the ESE in vivo
mediates enhancement of splicing we tested a series of con-
structs where the murine EDA wild type 3P and 5P splicing
sites (SS) had been modi¢ed towards the consensus. The nat-
ural 5P SS (CAG:GTATAT) was mutated to CAG:G-
TAAGT. This structural variant has improved base comple-
mentarity to U1 RNA. The 3P SS of the FN-EDA exon was
replaced by the 3P SS of the constitutively spliced-in second
exon of the Apo A1 gene (Fig. 1 and Section 2). This change
should provide a stronger 3P splicing site to the EDA exon.
The constructs with the consensus 3P SS or the 5P SS stimu-
lated constitutive exon inclusion in transient transfection ex-
periments (Fig. 3, lanes 3^5). The EDA exon was constitu-
tively included in the construct where the natural FN 3P or the
5P splicing sites were replaced by stronger ones. As expected,
this high splicing e⁄ciency was also observed in a construct
bearing both the 3P and 5P consensus splicing sites. Thus,
increased U1 RNA complementarity and 3P splicing site
strength stimulate the rate of exon inclusion, resulting in
both cases in uniform selection of the EDA exon.
Surprisingly when the ESE was deleted in the constructs
shown above (see Fig. 3, lanes 8^12, pSVED-mEDA-vA-
5PSScons, pSVED-mEDA-vA-3P+5PSScons and pSVED-
mEDA-vA-3PSScons plasmids), constitutive exon inclusion
was only obtained with the constructs bearing a strong 5P
splicing site. In e¡ect, the pSVED-mEDA-vA-3PSScons con-
structs were not able to fully stimulate splicing in order to
obtain constitutive inclusion (Fig. 3, lanes 11 and 12). It can
be seen also that when the ¢rst base of the exon is a G instead
of the A found in the wt sequence there is a stimulation in
splicing, suggesting that the e⁄ciency of spliceosome forma-
tion is a¡ected in the construct containing the A as ¢rst base
of the exon. In the pSVED-mEDA-vA-5PSScons construct,
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Fig. 1. Mouse vs Human comparison of the splicing elements that controls alternative splicing of the EDA exon. A schematic representation of
the EDA region of mouse FN gene is shown. The sequence of the mouse and human 3P and 5P splicing sites is compared with the consensus
sequence, and the exonic region sequence involved in EDA splicing regulation is indicated for the mouse and human exons. Enhancer (A ele-
ment) and silencer (B element) sequences are underlined. Human and mouse elements are indicated as Ah, Bh, and Am, Bm respectively. Indi-
vidual base frequencies are also indicated. FN exons and introns are shown as boxes and lines respectively.
Fig. 2. Expression of the mouse EDA minigene variant in NIH3T3
cells. Schematic representation of the modi¢cations introduced in
the various minigene constructs. The thin lanes and shaded boxes
represent intron and exon sequences respectively. The white or
hatched boxes within the exons indicate mouse or human A and B
elements respectively (upper panel). RT-PCR analysis of total RNA
from cells expressing each of the indicated constructs in NIH3T3
cell line (lanes 1^7). Arrows indicate PCR products either contain-
ing or lacking the FN EDA exon in the messenger transcribed from
the transfected minigene. Lane 8 corresponds to mock-transfected
cells. A 1 kb ladder (BRL) was used as molecular weight marker
(lower panel).
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which has a deletion in the ESE and a strong 5P splicing site,
the EDA exon is spliced in with an exceptionally high e⁄-
ciency (Fig. 3, lane 8), similar to the one obtained with the
pSVED-mEDA-5PSScons or the any of the double splicing site
modi¢ed constructs. Similar results were obtained by trans-
fecting di¡erent cell types, regardless of the endogenous pat-
tern of EDA alternative splicing (not shown). These results
may indicate ¢rstly that the SR proteins that recognise the
ESE cooperate with the 5P SS in the formation of the early
splicing complex, and secondly that stimulation of splice-
osome assembly occurs with the 3P SS. Moreover, this co-
operation seems to be a general mechanism in di¡erent cell
types.
4. Discussion
The EDA exon sequence of the FN gene is highly conserved
among di¡erent species, moreover the conserved splicing pat-
tern may re£ect a common evolution of the alternative splic-
ing control mechanism. Despite these observations, compari-
son of the EDA sequences at the previously reported human
exonic regulatory splicing elements showed single base
changes in the core sequence of both the ESE and the ESS.
Furthermore, comparison with other species also showed im-
perfect matching of the ESE sequences (see also Fig. 3 of
Lavigueur et al. [8]). We have analysed if these minimal
base changes were re£ected as di¡erent regulatory splicing
mechanisms in the mouse EDA exon. The introduction of
the human sequence in the mouse A (ESE) and B (ESS) ele-
ments did not have signi¢cant consequences for splicing e⁄-
ciency. Deletion of the mouse ESE has the same in vivo e¡ect
as the human counterpart. In fact, both in the human
pSVED-v2e [2] and in the mouse pSVED-vA constructs
(both bearing a deletion of the A element), the EDA exon
was constitutively skipped.
It has been shown [8] that the purine-rich element of the
human EDA exon in both in vitro splicing and gel shift assays
favours the selection of the 3P splicing site of the EDA exon
by establishing U2 RNA and U2AF65 binding, and this e¡ect
is mediated by SR proteins speci¢cally recognising this ele-
ment. There are also other examples that show that SR pro-
teins bound to exonic enhancers can promote an interaction
of the U2 snRNA, U2AF65 and U2AF35, promoting the rec-
ognition of the 3P splicing site [30^32]. All these experiments
were carried out in in vitro systems, utilising a two exons-one
intron RNA transcript structure that does not resemble the
three exons-two introns natural con¢guration of the EDA
alternative splicing. The in vitro systems may overlook some
of the ¢ne mechanism that control alternative splicing. In fact,
substrates having short truncated second exons function via
direct intron de¢nition, bypassing the exon de¢nition model.
Indeed, bypassing exon de¢nition requires short introns and
most in vitro experiments use internally deleted introns to
maximise complex formation and activity [33]. In our case
we utilised more physiological conditions, as in vivo assays,
the complete genomic region containing the internal EDA
exon plus its £anking exons, as well as the complete intronic
intervening sequences. The results shown in Fig. 3 demon-
strate in vivo that the ESE stimulates the recognition of the
5P splicing site of the EDA exon. The presence of a strong 3P
splicing site is not enough to compensate for the absence of
the ESE sequence. In contrast, a strong 5P splicing site over-
comes the ESE requisite. This may indicate that the trans-
acting factors that recognise the ESE primarily cooperate
with the 5P splicing site, probably stimulating the binding of
U1 RNA, as reported for the other examples [10,13,14], and
secondly they could act as bridging factors across the entire
exon to facilitate 3P splicing site recognition. Furthermore, the
cooperative role of the ESE and the 5P splicing site seems to
be a widespread mechanism among di¡erent cell types. Vari-
ous laboratories have demonstrated that the strength of a 5P
splicing site a¡ects recognition of the upstream intron consis-
tent with a model proposing interactions across the exon [34^
36]. Base pairing of the U1 RNA with the 5P splicing site can
stimulate binding of the general splicing factor U2AF65 to the
polypyrimidine tract of the preceding intron [37]. This inferred
interaction between U1 snRNA and U2AF65 is indirect and
requires additional proteins [37]. In vitro experiments support
the possibility that members of the SR family of proteins can
provide a bridging function [38,39]. In vivo experiments dem-
onstrating the splicing enhancer e¡ect of purine-rich exonic
elements and the importance of the splicing sites have been
performed by di¡erent groups [3,6,21,40^45]. Dominiski and
Kole [43] showed that the presence of either a strong poly-
pyrimidine tract or a consensus 5P splicing site compensates
for the absence of exonic sequences after deletion of the major
part of an arti¢cial globin-derived internal exon. In our FN-
EDA model the presence of a strong polypyrimidine tract
enhanced exon inclusion, although it did not compensate for
the absence of the well-de¢ned polypurinic enhancer element.
Despite the di¡erences in exon-intron structure, our results
are in agreement with those of Dirksen et al. [46,47], who
showed by transient transfection experiments that in the
case of the bovine growth hormone gene, where an ESE is
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Fig. 3. Cooperation between splicing sites and the enhancer splicing
element. Splicing site modi¢ed minigene constructs (upper panel)
were transiently transfected into NIH3T3 cells and the produced
RNA was analysed by RT-PCR (lower panel). Modi¢ed splicing
sites are represented as light grey boxes at the splice junctions. Ar-
rows indicate the splicing variants that contained EDA or skipped
it. Lanes 1^12 show the analysis of the transfection of the di¡erent
splicing-enhancer element mutant constructs. Mock-transfected cells
are shown in lane 13. The A and B elements (A; B), and XhoI site
are indicated (X). Lanes 3, 5, 6, 8, 9 and 10 show a minor larger
extra band that corresponds to the 587 bp splicing product that uti-
lises a 3P cryptic site located 132 bases upstream of the natural
EDA +1 exon 3P splicing site. A 1 kb ladder (BRL) was used as
molecular weight marker.
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located in the fourth and last exon, the purine-rich element
compensates for a weak 5P splicing site in the preceding exon.
These contrasts may indicate that particular ESE-splicing site
interactions occur in di¡erent systems.
In conclusion, the mouse and human FN alternative splic-
ing regulation is essentially conserved. The elements involved
are exonic sequences, particularly but not exclusively a poly-
purinic enhancer, and suboptimal 5P and 3P splice junctions.
The experiments in vivo indicate a critical role for the coop-
eration between the EDA polypurinic exonic splicing en-
hancer and its 5P splicing site, which predominates over the
3P splicing site.
These results make approachable the study of the biological
signi¢cance of alternative splicing using germ line manipula-
tion. Our current knowledge will allow us to radically modify
the FN alternative splicing pattern without changing the ami-
no acid sequence of the FN isoforms, and with minimal in-
terference on the RNA sequence.
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